Rutgers Biomedical and Health Sciences

QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

Retrieved on: 
Tuesday, January 10, 2023
Plasma protein binding, National Cancer Institute, Cleveland Clinic, Prostate, NCI, NCI-designated Cancer Center, Neoplasm, Priority review, Death, Safety, PRV, Breast, Health, FDA, Rutgers Cancer Institute of New Jersey, QSAM, Lung, FN1, Drug development, Conference, 2A, Bone, Growth, Cleveland, Patient, Radiation, Rutgers Biomedical and Health Sciences, Cancer, OTCQB, Graphite-moderated reactor, Orphan drug, Pain, Medical imaging, Food delivery, Pharmaceutical industry

AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.

Key Points: 
  • AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of bone cancer and related diseases, today provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.
  • We are pleased to provide you with an update on QSAM Biosciences’ progress over the last year and what you can expect from us in 2023.
  • We are looking forward to progress in 2023 which we expect will create fundamental value for our shareholders.
  • Thank you again for your support, and from all of us at QSAM, we wish you a happy, healthy and prosperous 2023.

QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer

Retrieved on: 
Wednesday, October 26, 2022
Lung, Rutgers Cancer Institute of New Jersey, QSAM, Clinical trial, Health, National Cancer Institute, OTCQB, MD, Cancer, Cleveland, American Cancer Society, CEO, Patient, Bone, Osteosarcoma, Cleveland Clinic, Rutgers Biomedical and Health Sciences, Technology, Breast, Prostate, Dog, News, GLOBE, Haematopoietic system, Risk, Â, Therapy, FDA, Notice, Population, Knowledge, Intention, Time, NCI-designated Cancer Center, NCI, Radiation, Pharmaceutical industry, Medical imaging, Rutgers University

QSAMs study is a multiple center, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam in patients, and also assess early efficacy signals.

Key Points: 
  • QSAMs study is a multiple center, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam in patients, and also assess early efficacy signals.
  • Patients with bone cancer that has metastasized from the breast, prostate, lung, or other organs are eligible to enroll in the study.
  • Additionally, osteosarcoma and Ewings Sarcoma bone cancer patients, diseases that mostly affect children and young adults, are also eligible.
  • "The addition of Rutgers as our second clinical trial site will allow us to advance our study more rapidly in this major northeast population center, stated Douglas R. Baum, CEO.

HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Retrieved on: 
Monday, September 12, 2022
Rutgers Biomedical and Health Sciences, FDA, Center, HSCS, United States Joint Congressional Committee on Inaugural Ceremonies, Robert Wood Johnson University Hospital, Hypertension, Industry, Diabetes, Mayo Clinic Center for Innovation, Degenerative disease, CEO, Technology, Cardiology, ECG, Innovation Center station, Robotics, Artificial intelligence, NASDAQ, LVDD, Heart, GLOBE, Ischemia, Rutgers University, Innovation, Medical device, Pharmaceutical industry

The Center is designed to encourage a multidisciplinary approach where clinicians work with industry to investigate and apply new technologies, to solve medical problems.

Key Points: 
  • The Center is designed to encourage a multidisciplinary approach where clinicians work with industry to investigate and apply new technologies, to solve medical problems.
  • We are currently working with the Rutgers Health network, which includes the Robert Wood Johnson University Hospital, as part of our FDA pivotal validation study and applaud their commitment to the latest technologies.
  • We are excited to participate in the celebration of this Innovation Center and showcase the MyoVista, as we continue to strengthen our relationship with Rutgers, stated Mr. Andrew Simpson, CEO of HeartSciences.
  • Robert Wood Johnson University Hospital is one of the institutions participating in HeartSciences pivotal study related to FDA submission.

Graham-Pelton names Walt Edwards President

Retrieved on: 
Monday, August 1, 2022
Philadelphia, View, University, Case Western Reserve University, Weatherhead School of Management, Rutgers Biomedical and Health Sciences, Talent, H. Lee Moffitt Cancer Center & Research Institute, Industry, Vanderbilt University Medical Center, Training and development, Beth Israel Deaconess Medical Center, Culture, Partnership, Case Western Reserve University School of Law, Multimedia, The Ride to Conquer Cancer, Hospital, Assistant, Emory Healthcare, Dana–Farber Cancer Institute, Children's Hospital of Orange County, Leadership, Moses Austin, Children's Hospital of Philadelphia, Orange County, Colby College, Growth, USF Health Byrd Alzheimer's Institute, University of Pennsylvania Health System, Pharmaceutical industry, Interior design, Management, Collegium (ancient Rome)

NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Leading global fundraising consulting firm Graham-Pelton announced today the appointment of Walt Edwards as its president.

Key Points: 
  • NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Leading global fundraising consulting firm Graham-Pelton announced today the appointment of Walt Edwards as its president.
  • Leading global fundraising consulting firm Graham-Pelton announces the appointment of Walt Edwards as its president.
  • "Walt is the right leader for this next stage in Graham-Pelton's history," said Graham-Pelton founder, Craig Leach.
  • "It's a pleasure to be named president of a firm as globally recognized and distinguished as Graham-Pelton," said Edwards.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Expansive, Diverse and Compelling New Cancer Research at the 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Bleomycin, Lymphoma, Physician, Cancer, Multiple myeloma, Education, Master of Science, RWJBarnabas Health, Children's Oncology Group, Daratumumab, Medicine, Annual general meeting, Social media, Population, Associate Director of National Intelligence and Chief Information Officer, Survival, CPI, Rutgers Biomedical and Health Sciences, 2021 Essex County Council election, Patient, Hodgkin lymphoma, Health, FACP, Associate, Lung cancer, Society, Oncology, Rutgers Cancer Institute of New Jersey, American Society of Clinical Oncology, Adult, CHL, Research, Pembrolizumab, DO, Brentuximab vedotin, Immunity, Leukemia, Safety, ASCO, Prognosis, Colorectal cancer, LL, ALL, Acute leukemia, Trial of the century, Outline of health sciences, SUMO protein, Pharmaceutical industry, Medical imaging

NEW BRUNSWICK, N.J., May 26, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present intriguing data from their innovative cancer clinical research program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 3-7. A total of 14 presentations, including 13 abstracts and one education session, have been accepted, highlighting research advances in several types of cancer, including leukemia, lymphoma, lung cancer and colorectal cancer.

Key Points: 
  • NEW BRUNSWICK, N.J., May 26, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present intriguing data from their innovative cancer clinical research program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 3-7.
  • A total of 14 presentations, including 13 abstracts and one education session, have been accepted, highlighting research advances in several types of cancer, including leukemia, lymphoma, lung cancer and colorectal cancer.
  • "The high-powered lineup of valuable data to be unveiled at this year's ASCO Annual Meeting reflects the command of medicine, technical expertise and leading-edge thinking that are the hallmarks of our cancer research program.
  • The full list of presentations at the 2022 ASCO Annual Meeting follows:

NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets

Retrieved on: 
Tuesday, February 1, 2022
ACT, Rutgers Cancer Institute of New Jersey, Private Securities Litigation Reform Act, Forward-looking statement, RWJBarnabas Health, Patient, Proton therapy, CAR, Rutgers University, Nanoparticle, Haematopoietic system, Robert Wood Johnson University Hospital, NEXI, Infection, Neoplasm, Toxic epidermal necrolysis, Cancer, National Cancer Institute, SEC, R, AIM, Immunotherapy, Technology, Outline of health sciences, Teaching hospital, U.S. Securities and Exchange Commission, Rutgers Biomedical and Health Sciences, Annual report, Precision medicine, NCI-designated Cancer Center, Company, GLOBE, Degenerative disease, State university system, Senior, Cancer Institute, Survival, Security (finance), Therapy, Terminology, AML, Wilms' tumor, Multiple myeloma, Nasdaq, Vaccine, Pharmaceutical industry

The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers.

Key Points: 
  • The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers.
  • Neuroendocrine tumors are being diagnosed with increasing frequency in the United States and represent a large unmet medical need, said Dr. Jerry Zeldis, NexImmunes Executive Vice President, R&D.
  • With Dr. Libutti, we hope to discover and develop novel treatments utilizing our AIM ACT platform that may improve the timely and effective treatment of neuroendocrine neoplasia.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Arturo Brito, MD, MPH, Appointed President and CEO of Children's Health Fund

Retrieved on: 
Thursday, August 19, 2021
Rutgers Biomedical and Health Sciences, University, Health, Quality of life, Infant, Racism, Infection, National health insurance, Trauma, Leadership, Policy, DNA, Children's Health Fund, Outline of health sciences, Mental health, MPH, Learning, Multimedia, Foundation, State government, COVID-19 testing, CHF, CEO, National Network, Health equity, New Jersey Department of Health, School, COVID-19, View, Pharmaceutical industry, Management, Medicine, Vaccine

Before joining The Nicholson Foundation, he served as deputy commissioner for Public Health Services of the New Jersey Department of Health.

Key Points: 
  • Before joining The Nicholson Foundation, he served as deputy commissioner for Public Health Services of the New Jersey Department of Health.
  • In addition to these accomplishments, Dr. Brito provided essential leadership to Children's Health Fund from 2006 to 2011 as its chief medical officer and executive vice president.
  • -Mary O'Dowd, MPH, former New Jersey health commissioner, and current executive director, Health Systems and Population Health Integration, Rutgers Biomedical and Health Sciences
    "Dr. Brito's experience focuses on leveraging partnerships to transform child health.
  • In times of emergency, Children's Health Fund mobilizes to ensure partners have the resources and tools to provide care to those most in need.

N8 Medical Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board

Retrieved on: 
Thursday, November 8, 2018
University of Medicine and Dentistry of New Jersey, Biological hazards, Safety, Healthcare in New York City, Public Health Research Institute, New Jersey Medical School, NEW JERSEY, Biodefense, Biocontainment, Rutgers Biomedical and Health Sciences

Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases who has played a major role in advancing the national research agenda in biodefense and emerging infectious diseases.

Key Points: 
  • Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases who has played a major role in advancing the national research agenda in biodefense and emerging infectious diseases.
  • He is executive director of the Public Health Research Institute (PHRI) and the Rutgers Regional Biocontainment Laboratory of New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences.
  • Dr. Perlin joins Dr. Michael Niederman, who chairs the N8 Medical SAB.
  • He is on the editorial board of several scientific journals and serves on boards of prominent medical and research institutes and industry companies.